MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. by Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, Bettina L Lee, Dieter Demon, Amelie Fossoul, Filip Van Hauwermeiren, Pedro H V Saavedra, Petr Šimon, Vladimír Šubrt, Libor Kostka, Craig E Stivala, Victoria C Pham, Steven T Staben, Sayumi Yamazoe, Jan Konvalinka, Nobuhiko Kayagaki, Mohamed Lamkanfi

Get full text